Esophageal Cancer Clinical Trial
Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR Imaging
Summary
The purpose of this study is to find out whether sentinel lymph node (SLN) mapping with ICG dye and NIR imaging can be used to identify esophageal or esophagogastric junction cancer that has spread to the lymph nodes. If SLN mapping is successful in these types of cancer, surgeons in the future could identify the sentinel lymph nodes and only remove these instead of removing all the lymph nodes which is currently done.
Eligibility Criteria
Inclusion Criteria:
Pathological diagnosis of adenocarcinoma tumor located in distal 1/3 of esophagus or esophagogastric junction , with a plan to undergo minimally invasive esophagectomy.
All patients with Stage IVA (AJCC Cancer Staging Manual, 8th edition) disease will be eligible
≥18 years of age.
Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study and for standard surgical resection.
Exclusion Criteria:
No plan to undergo surgical resection.
Severe iodide or seafood allergy.
Women of childbearing potential without a negative pregnancy test; or women who are lactating.
Prior diagnosis of severe hepatic or renal dysfunction.
Patients with Stage IVB or M1 disease (AJCC Cancer Staging Manual, 8th edition)
Patients with local recurrence and planning to undergo salvage esophagectomy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10065, United States More Info
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.